Entospletinib,Lanraplenib
Kronos Bio,gilead
[]
kronos bio continues to advance investigational syk inhibitors entospletinib and lanraplenib with new preclinical data at eha2022 congress $kron 
Run by investors, for investors.

Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more

Not investment advice